Acerta News

Latest Press Releases

 

June 15, 2019
Calquence significantly prolonged the time patients lived without disease progression in relapsed or refractory chronic lymphocytic leukaemia


June 6, 2019
Calquence Phase III ELEVATE-TN trial met primary endpoint at interim analysis in previously-untreated chronic lymphocytic leukaemia


May 16, 2019
AstraZeneca continues to redefine cancer treatment at the 2019 ASCO Annual Meeting


May 10, 2019
Forty Seven Inc. and Acerta Enter Collaboration to Evaluate Novel Immuno-Oncology Triple Combination in Diffuse Large B-cell Lymphoma


May 7, 2019
CALQUENCE Phase III ASCEND trial met primary endpoint at interim analysis in relapsed or refractory chronic lymphocytic leukaemia and will stop early


March 28, 2019
CureSearch for Children’s Cancer Launches Groundbreaking IMPACT Series Forum


December 3, 2018
New long-term data on CALQUENCE presented at ASH 2018


November 27, 2018
AstraZeneca presents clinical research advances for blood cancer patients at 2018 American Society of Hematology Annual Meeting


October 31, 2017
US FDA Approves AstraZeneca’s CALQUENCE® (acalabrutinib) For Adult Patients With Previously-Treated Mantle Cell Lymphoma


August 2, 2017
US FDA Accepts Regulatory Submission For Acalabrutinib And Grants Priority Review


August 1, 2017
Acalabrutinib granted Breakthrough Therapy Designation by US FDA for the treatment of patients with Mantle Cell Lymphoma


December 5, 2016
Early Data Demonstrate Clinical Activity Of Acalabrutinib In Difficult-To-Treat Chronic Lymphocytic Leukaemia


September 27, 2016
AstraZeneca to strengthen presence in California with new South San Francisco location


February 25, 2016
Acalabrutinib recommended for orphan drug designation in Europe for three indications


February 2, 2016
AstraZeneca completes transaction for majority equity stake investment in Acerta Pharma


December 17, 2015
AstraZeneca enhances long-term growth through Oncology investment in Acerta Pharma


December 7, 2015
Acerta Pharma Announces Study Published in New England Journal of Medicine Demonstrates Acalabrutinib (ACP-196) Shows Marked Activity in Relapsed Chronic Lymphocytic Leukemia

Publications

Recent publications from Acerta Pharma.

Read More

Community Outreach

Acerta Pharma is dedicated to making a positive impact, including in our community. We support various patient advocacy and non-profit organizations in their noble efforts.

Read More